Efecto de clobenzorex y melatonina sobre la expresión génica y actividad enzimática de NADPH oxidasa y óxido nítrico sintasa en personas obesas

Abstract

Obesity is a chronic disease that is established by an imbalance between intake and energy expenditure, increases the risk of producing disorders such as insulin resistance and elevated cholesterol, which lead to the development of other diseases such as cardiovascular disease, diabetes and cancer. Some of the complications and microvascular MarcR presented in these diseases are triggered from an inflammatory response that leads to excessive production of free radicals (FR) generated primarily by the enzyme systems nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and nitric oxide synthase (NOS). Consequently, there will be a steady and progressive vascular damage that cause endothelial dysfunction. Since then the important role of these enzymes in the development of vascular injury, this study was aimed to evaluate the activity and gene expression of NADPH oxidase and NOS in a group of obese people clobenzorex treated (drug control weight) and melatonin (an antioxidant) for 3 months. For this purpose, quantified the content of hemoglobin-nitric oxide complex (Hb-NO •) and NADPH oxidase activity by electron paramagnetic resonance spectroscopy (EPR), hemoglobin content, protein, nitrate and nitrite by ultraviolet spectrophotometry -visible and gene expression of the subunits p22phox, p47phox and Nox1 NADPH oxidase and the inducible NOS by the technique of chain reaction (PCR). The results showed a decrease in the activity of NADPH oxidase and NOS (measured indirectly), and gene expression of both enzymes. Therefore, these results suggest that simultaneous administration of melatonin clobenzorex and are a good alternative as a treatment for the prevention of obesity-associated comorbidities.